Current Events Pharmaceuticals

“Black Market” Pharmaceuticals

In June of 2005, a pharmaceutical named BiDil used to combat heart failure was approved by the FDA. While this is not a notable event—there are many drugs to treat heart failure—the approval is novel since it was only approved for African-American patients. According to the Kaiser Family Foundation, the FDA “…approved BiDil for use in black patients based on the results of a clinical study sponsored by the drug’s manufacturer NitroMed, which found the medication reduced deaths by 43% within one year of use among black patients who had tried other medications.”

The FDA approval has generated some controversy. Should there be race-specific drugs? Can citizens trust government agencies to decide which pharmaceuticals are beneficial for which races? Which drugs are acceptable for individuals who are classified as ‘mixed race?’

The NAACP has overwhelmingly supported BiDil (see NitroMed website and a Boston-Bay State Banner newspaper report) and hopes to expand . A recent article in the Annals of Internal Medicine (“BiDil for Heart Failure in Black Patients“) gives the FDA’s perspective:

“Critics of the U.S. Food and Drug Administration (FDA) approval of the fixed combination of hydralazine hydrochloride, 37.5 mg, and isosorbide dinitrate, 20 mg, for treating heart failure in black patients have suggested that data were insufficient to distinguish treatment effects in black and white people; that distinctions based on race, rather than pathophysiology, were scientifically unreasonable; and that a “race-based” approval could be a commercial ploy to avoid a more expensive and prolonged full evaluation of a drug. The criticisms acknowledge that data supporting the approval came from a well-designed clinical trial in which self-identified black patients with heart failure who took hydralazine hydrochloride–isosorbide dinitrate with standard therapy experienced a statistically significant 43% (95% CI, 11% to 63%) reduction in mortality compared with those who took only the standard therapy. The criticisms do not always recognize that the decision to conduct the trial in only black patients reflected careful analyses of 2 previous trials in racially mixed patient populations that compared hydralazine hydrochloride–isosorbide dinitrate with placebo or with enalapril. Both trials showed little or no overall effect of hydralazine hydrochloride–isosorbide dinitrate in the mostly white patient population but hinted at a substantial effect in subsets of black patients. Perhaps most critically, the criticisms do not appreciate the urgency of strong scientific evidence of a substantial survival benefit in black patients. A serious attempt to avoid race-based approval by mandating study of a mixed population to identify a possible white patient–responder subset, particularly without a plausible hypothesis as to what that subset might be, would have required years of work, many thousands of patients, and wholly unreasonable delay in approval of a treatment whose effectiveness had been well-documented in the group for which it was intended.”


Comments are closed.